The study was powered to detect overall objective response rate ( ORR ) in the glembatumumab vedotin arm between 10 % ( null ) and 22.5 % ( alternative hypothesis ) with preplanned investigation of activity by gpNMB distribution and/or intensity ( Stratum 1 to Stratum 3 ) .